Skip to content
DraconiticResearch
Search Sources API
194,226 studies31 sourcesUpdated 9 min ago
Peer-reviewedCC BYHematology, Transfusion and Cell Therapy

AUTOLOGOUS STEM CELL TRANSPLANTATION REMAINS AN EFFECTIVE STRATEGY IN MANTLE CELL LYMPHOMA IN A BRAZILIAN REAL-WORLD COHORT

  • Lara GALLUCCI FIGORELLE1
  • Ruddy DALFEOR2
  • Valéria VIANNA1
  • Verena PFISTER3
  • Jéssica LOUREIRO1
  • Danielle LEãO4
  • Renata LYRIO5
  • Rafaella SAMICO6
  • Vitória SIQUEIRA7
  • Mariana GARANá8
  • Daniel MERCANTE9
  • Celso ARRAIS10
5 more authors
  • Lisa RICCI11
  • Alexandre JUNQUEIRA NEVES9
  • Kátia CARNEIRO1
  • Cristiane MILITO1
  • Rony SCHAFFEL1
11 affiliations
  1. 1Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  2. 2Centro de Tratamento Oncológico, Rio de Janeiro, RJ, Brazil
  3. 3Registro Brasileiro de Linfoma de Células do Manto, Departamento de Registros, Associação de Hematologia, Hemoterapia e Terapia Celular, São Paulo, SP, Brazil
  4. 4Beneficência Portuguesa de São Paulo, São Paulo, SP, Brazil
  5. 5Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  6. 6Hospital Universitário de Brasília, Brasília, DF, Brazil
  7. 7Hospital Ophir Loyola, Para, PA, Brazil
  8. 8Hospital Universitário Gaffrée e Guinle, Rio de Janeiro, RJ, Brazil
  9. 9Hospital Universitário Antônio Pedro, Niteroi, RJ, Brazil
  10. 10Hospital Nove de Julho, São Paulo, SP, Brazil
  11. 11Instituto de Oncologia de Sorocaba, Sorocaba, RJ, Brazil
Read full textDOICite

Abstract

Autologous stem cell transplantation (ASCT) remains a consolidation strategy in mantle cell lymphoma (MCL), although recent studies have questioned its role in the era of targeted therapies. However, in settings with heterogeneous access to treatment, such as Brazil, ASCT may still influence real-world outcomes. We evaluated the impact of ASCT, treatment intensity, access to therapy, and differences between public and private healthcare systems in Brazilian patients with MCL. Clinical data from 229 patients included in the Brazilian MCL registry were analyzed. After exclusion of cases with insufficient data or rapidly progressive disease, 198 patients were stratified into three groups: first-line ASCT (ASCT group), ASCT-ineligible patients (>70 years; ineligible group), and transplant-eligible patients who did not undergo ASCT (non-ASCT group). Median overall survival (OS) and progression-free survival (PFS) for the overall cohort were 52.8 and 21.0 months, respectively. Median OS was 98.4, 47.4, and 41.8 months for the ASCT, ineligible, and non-ASCT groups, respectively. Median PFS was 36.0, 16.4, and 15.2 months. The ASCT group showed superior OS and PFS compared to the other groups (P=0.019 and P<0.001). Among non-transplanted patients, high-intensity chemotherapy did not improve OS or PFS compared to conventional regimens. In contrast, ASCT was associated with superior OS and PFS versus non-transplanted patients (OS: 98.4 vs. 43.6 months, P=0.008; PFS: 36.0 vs. 16.4 months, P=0.044). Preliminary analyses suggest favorable response to induction therapy as the main reason for not proceeding to ASCT, followed by early disease progression. Updated analyses with additional patients and reasons for ASCT omission will be presented at the congress.

Related

  1. On closing the gap: anti-PD-1-based salvage in relapsed/ refractory classical Hodgkin lymphoma. Comment on: “Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma”
    Hishan Tharmaseelan, Bastian von Tresckow
    HaematologicaPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
  2. The gap narrows but shifts. Response to Comment on: “Mind the gap: anti–PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma”
    Daniel Noerenberg
    HaematologicaPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
  3. Follicular Lymphoma Presenting as Refractory Panniculitis-like Lesions: A Case Report of Successful Salvage with Autologous Stem Cell Transplantation
    Kristina Alaiyoud, Nikolett Farmasi, Zsófia Miltényi +3
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  4. Oral versus intravenous melphalan for autologous stem cell transplantation conditioning in lymphoma and multiple myeloma: a retrospective cohort study
    Jingrong Wang, Yimeng Guo, Jin Zhao +4
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMCEurope PMC
  5. Nutritional Risk, Weight Loss, and Inflammatory Profiles During Autologous Stem Cell Transplantation: Clinical Correlates in Patients with Lymphoma and Multiple Myeloma
    Berrin Balik, Defne Beybolat, Osama Alabdullah +12
    NutrientsPeer-reviewedCC BY 4.0NutritionCrossref

Cite

BibTeXRIS
BibTeX
@article{figorelle2026autologous,
  title = {{AUTOLOGOUS STEM CELL TRANSPLANTATION REMAINS AN EFFECTIVE STRATEGY IN MANTLE CELL LYMPHOMA IN A BRAZILIAN REAL-WORLD COHORT}},
  author = {Lara GALLUCCI FIGORELLE and Ruddy DALFEOR and Valéria VIANNA and Verena PFISTER and Jéssica LOUREIRO and Danielle LEãO and Renata LYRIO and Rafaella SAMICO and Vitória SIQUEIRA and Mariana GARANá and Daniel MERCANTE and Celso ARRAIS and Lisa RICCI and Alexandre JUNQUEIRA NEVES and Kátia CARNEIRO and Cristiane MILITO and Rony SCHAFFEL},
  journal = {Hematology, Transfusion and Cell Therapy},
  year = {2026},
  month = oct,
  doi = {10.1016/j.htct.2026.107737},
  url = {https://doi.org/10.1016/j.htct.2026.107737},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - AUTOLOGOUS STEM CELL TRANSPLANTATION REMAINS AN EFFECTIVE STRATEGY IN MANTLE CELL LYMPHOMA IN A BRAZILIAN REAL-WORLD COHORT
AU  - Lara GALLUCCI FIGORELLE
AU  - Ruddy DALFEOR
AU  - Valéria VIANNA
AU  - Verena PFISTER
AU  - Jéssica LOUREIRO
AU  - Danielle LEãO
AU  - Renata LYRIO
AU  - Rafaella SAMICO
AU  - Vitória SIQUEIRA
AU  - Mariana GARANá
AU  - Daniel MERCANTE
AU  - Celso ARRAIS
AU  - Lisa RICCI
AU  - Alexandre JUNQUEIRA NEVES
AU  - Kátia CARNEIRO
AU  - Cristiane MILITO
AU  - Rony SCHAFFEL
PY  - 2026
DA  - 2026/10/23
JO  - Hematology, Transfusion and Cell Therapy
DO  - 10.1016/j.htct.2026.107737
UR  - https://doi.org/10.1016/j.htct.2026.107737
AB  - Autologous stem cell transplantation (ASCT) remains a consolidation strategy in mantle cell lymphoma (MCL), although recent studies have questioned its role in the era of targeted therapies. However, in settings with heterogeneous access to treatment, such as Brazil, ASCT may still influence real-world outcomes. We evaluated the impact of ASCT, treatment intensity, access to therapy, and differences between public and private healthcare systems in Brazilian patients with MCL. Clinical data from 229 patients included in the Brazilian MCL registry were analyzed. After exclusion of cases with insufficient data or rapidly progressive disease, 198 patients were stratified into three groups: first-line ASCT (ASCT group), ASCT-ineligible patients (>70 years; ineligible group), and transplant-eligible patients who did not undergo ASCT (non-ASCT group). Median overall survival (OS) and progression-free survival (PFS) for the overall cohort were 52.8 and 21.0 months, respectively. Median OS was 98.4, 47.4, and 41.8 months for the ASCT, ineligible, and non-ASCT groups, respectively. Median PFS was 36.0, 16.4, and 15.2 months. The ASCT group showed superior OS and PFS compared to the other groups (P=0.019 and P<0.001). Among non-transplanted patients, high-intensity chemotherapy did not improve OS or PFS compared to conventional regimens. In contrast, ASCT was associated with superior OS and PFS versus non-transplanted patients (OS: 98.4 vs. 43.6 months, P=0.008; PFS: 36.0 vs. 16.4 months, P=0.044). Preliminary analyses suggest favorable response to induction therapy as the main reason for not proceeding to ASCT, followed by early disease progression. Updated analyses with additional patients and reasons for ASCT omission will be presented at the congress.
SN  - 2531-1379
SN  - 2531-1387
ER  -